SEC Form 4 · accession 0001179110-16-024525
IDERA PHARMACEUTICALS, INC. · IDRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark J Casey
Officer — Senior VP & General Counsel
Period of report
May 12, 2016
Accepted (ET)
May 13, 2016 · 9:00 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000861838
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 12, 2016 | P | 34,450 | $1.44 | A | 34,450 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction reported herein reflects an aggregate purchase of shares at per share prices ranging from $1.35 to $1.48 inclusive. The Reporting Person further undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full disclosure with respect to the manner of shares purchased at each separate price.